A Phase 1/2 Study of In Situ Vaccination with Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects with Advanced, Measurable, Biopsy-accessible Cancers

IRB/UVA Tracking #
19276
Contact
Adela Mahmutovic
Contact Email
Contact Phone
Phase
I/II
Primary purpose
Treatment
Cancer PI
Elizabeth M Gaughan
Status
OPEN TO ACCRUAL
Ages
Adult